SAWC Fall: Oct 7-9, 2016; Las Vegas, NV
- Order Now
Your Source for Advanced Wound Care Products & Biotherapeutics
Monarch Labs was incorporated in September, 2005, as a producer and distributor of biotherapy medical products. The first and flagship product was Medical Maggots, originally studied at the University of California (UC Irvine) and the Department of Veterans Affairs (VA Medical Center, Long Beach, CA). After marketing clearance by the U.S. Food & Drug Administration (FDA), the production of Medical Maggots by the UC Irvine Maggot Therapy Laboratory was privatized by Monarch Labs.
In the brief period which followed, Monarch Labs has taken an additional three products to market (after obtaining FDA marketing clearance) and has begun studies with leech therapy and ichtiotherapy, as well.
For information about our products & services, check out our Products & Services page.
For a photo / video tour of Monarch Labs, check out our Lab Tour page.
For the latest news and developments at Monarch Labs, check out our News & Announcements page.
James Kuo, MD, MBA
Co-founder, Chairman and Director of Business Development
Dr. Kuo has over 20 years of experience in the life science industry as a venture capitalist, pharmaceutical business development executive and senior manager of private and publicly-traded biotech companies. Previously, he served as Chairman and Chief Executive Officer of Adeona Pharmaceuticals, a publicly-traded biotech company developing CNS therapies. Dr. Kuo is also a founder and served as Chairman and Chief Executive Officer of BioMicro Systems, a profitable genomic tools company. He is further a founder and served as Chief Executive Officer of Discovery Laboratories, a publicly-traded company developing surfactant-based respiratory therapeutics. Dr. Kuo has been Associate Director of Licensing and Development at Pfizer and Vice President of Business Development at Myriad Genetics. He was Managing Director of Venture Analysis at HealthCare Ventures, a venture capital firm with $378 million in funds under management. Dr. Kuo is a founder and Chairman of MSK Pharma, a private company developing pharmaceutical therapies for pain and musculoskeletal diseases. Dr. Kuo received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. from the Wharton School of Business. He received his B.A. in molecular biology from Haverford College.
Ronald A. Sherman, MD, MSc, DTM&H
Co-founder and Laboratory Director
Born in Los Angeles, Ronald Sherman earned his B.S. in Entomology at the University of California, Riverside, and his medical degree at UCLA. Between his internship in San Francisco, and his Internal Medicine Residency at UC Davis, he spent a year as a traveling general practitioner in Arizona, treating Native Americans, the Urban Poor, and the rural underserved. In 1988, Dr. Sherman completed the Masters Degree program in Clinical Tropical Medicine at the London School of Hygiene and Tropical Medicine, and also received his Diploma in Tropical Medicine and Hygiene from the Royal College of Physicians. After returning to the US in 1989, he trained as an Infectious Diseases Fellow at UC Irvine, during which time he began his clinical studies of maggot therapy. Dr. Sherman continued those studies as a Geriatrics and Infectious Diseases staff physician at the VA Medical Center, Long Beach. In 1995, he left the Department of Veterans Affairs and joined the Faculty at UC Irvine. With NIH funding, Dr. Sherman worked closely with Michael Selsted's research team as he studied the biochemistry underlying the maggots’ antimicrobial and wound-healing activity. Dr. Sherman continued his patient care activities by serving as an HIV/AIDS specialist for the Orange County Health Care Agency 1 or 2 days per week, where he continues to server to this day. In 2003, Dr. Sherman co-founded the BioTherapeutics, Education & Research (BTER) Foundation, a public charity whose mission is to advance health care through education and research in maggot therapy, leech therapy, and the other biotherapeutic modalities. He currently functions as its Board Chair and Director. Since 2004, production and distribution of Dr. Sherman's Medical Maggots has been regulated by the Food and Drug Administration. To meet the demand for maggots, and to uphold the high production standards required by the FDA, he co-founded Monarch Labs, for which he serves as the Laboratory’s Director. Dr. Sherman left his position at the University of California in July, 2008, in order to pursue his interests in teaching and research in biotherapy, and to optimize the quality control of Medical Maggots at Monarch Labs.